AZN vs. GMAB: AstraZeneca vs. Genmab Stock Comparison

November 11, 2026

How do AstraZeneca (AZN) and Genmab (GMAB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AstraZeneca (AZN) and Genmab (GMAB) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AZN is classified in Pharmaceuticals while GMAB is classified in Biotechnology.

Both AstraZeneca (AZN) and Genmab (GMAB) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Company profile comparison for AstraZeneca (AZN) and Genmab (GMAB)
Profile Item	AZN	GMAB
Name	AstraZeneca PLC American Depositary Shares	Genmab A/S American Depositary Shares
Country/Region	United Kingdom	Denmark
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Biotechnology
GICS Sub-Industry	Pharmaceuticals	Biotechnology
Market Capitalization	289.14 billion USD	32.98 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	May 12, 1993	June 1, 2009
Security Type	ADR	ADR

Price Performance

Cumulative Growth

AZN

GMAB

GSPC

AstraZeneca (AZN) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AstraZeneca (AZN) and Genmab (GMAB). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AstraZeneca (AZN) and Genmab (GMAB). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AstraZeneca (AZN) and Genmab (GMAB)
Metric	AZN	GMAB
Total Return (1Y)	12.64%	91.17%
Total Return (3Y, Annualized)	15.75%	20.70%
Total Return (5Y, Annualized)	10.63%	3.98%

Risk Profile

Drawdown History

AZN

GMAB

GSPC

AstraZeneca (AZN) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AstraZeneca (AZN) and Genmab (GMAB). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AstraZeneca (AZN) and Genmab (GMAB)
Metric	AZN	GMAB
Volatility (1Y, Annualized)	28.21%	45.68%
Beta (5Y)	0.22	0.72
Max Drawdown (5Y)	-27.87%	-61.79%
Avg. Volume (3M)	3.14M	4.09M

Risk-Adjusted Performance

Risk-Return Positioning

AZN and GMAB are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AstraZeneca (AZN) and Genmab (GMAB)
Metric	AZN	GMAB
Sharpe Ratio (1Y)	0.30	1.90
Sortino Ratio (1Y)	0.44	3.82

Profitability

ROE (TTM)

Both AstraZeneca (AZN) at 22.57% and Genmab (GMAB) at 12.07% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.57%

Max: 109.18%
AZN: 22.57%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.07%

Max: 109.18%
GMAB: 12.07%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both AstraZeneca (AZN) at 17.68% and Genmab (GMAB) at 16.97% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.68%

Max: 18.05%
AZN: 17.68%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.97%

Max: 18.05%
GMAB: 16.97%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both AstraZeneca (AZN) at 29.57% and Genmab (GMAB) at 37.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.57%

Max: 83.12%
AZN: 29.57%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.15%

Max: 83.12%
GMAB: 37.15%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AstraZeneca (AZN) and Genmab (GMAB)
Metric	AZN	GMAB
ROE (TTM)	22.57%	12.07%
ROA (TTM)	8.59%	8.24%
Net Margin (TTM)	17.68%	16.97%
Operating Margin (TTM)	29.57%	37.15%
Gross Margin (TTM)	81.78%	92.67%

Growth

Revenue Growth

Both AstraZeneca (AZN) at 8.63% and Genmab (GMAB) at 19.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both AstraZeneca (AZN) at 45.33% and Genmab (GMAB) at -9.23% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AstraZeneca (AZN) and Genmab (GMAB)
Metric	AZN	GMAB
Revenue Growth (YoY)	8.63%	19.19%
Revenue Growth (3Y CAGR)	9.82%	21.23%
EPS Growth (YoY)	45.33%	-9.23%
EPS Growth (3Y CAGR)	45.80%	8.48%

Financial Strength

Current Ratio (MRQ)

Both AstraZeneca (AZN) at 1.01 and Genmab (GMAB) at 2.45 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AZN: 1.01
Min: 0.10

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
GMAB: 2.45
Min: 0.10

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both AstraZeneca (AZN) at 0.66 and Genmab (GMAB) at 0.82 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.66

Max: 1.42
AZN: 0.66
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.82

Max: 1.42
GMAB: 0.82
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for AstraZeneca (AZN) and Genmab (GMAB)
Metric	AZN	GMAB
Current Ratio (MRQ)	1.01	2.45
Debt / Equity (MRQ)	0.66	0.82
Net Debt / EBITDA	1.23	2.45

Dividends

Dividend Yield (TTM)

Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73%

AZN: 1.73%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Genmab (GMAB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.38%

AZN: 45.38%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AstraZeneca (AZN) and Genmab (GMAB)
Metric	AZN	GMAB
Dividend Yield (TTM)	1.73%	0.00%
Dividend Payout Ratio (TTM)	45.38%	0.00%

Valuation

P/E Ratio (TTM)

AstraZeneca (AZN) at 26.37 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.37

Max: 85.34
Q3: 43.46
Median: 26.69
AZN: 26.37
Q1: 13.30
Min: 0.07

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.84

Max: 85.34
GMAB: 45.84
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both AstraZeneca (AZN) at 4.63 and Genmab (GMAB) at 7.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.63

Max: 58.18
Q3: 25.77
Median: 7.30
AZN: 4.63
Q1: 3.01
Min: 0.01

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.68

Max: 58.18
Q3: 25.77
GMAB: 7.68
Median: 7.30
Q1: 3.01
Min: 0.01

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both AstraZeneca (AZN) at 5.59 and Genmab (GMAB) at 5.36 are valued close to their industries’ norm against book — neither stands out from peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.59

Max: 13.53
Q3: 6.54
AZN: 5.59
Median: 3.25
Q1: 1.69
Min: -5.59

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.36

Max: 13.53
Q3: 6.54
GMAB: 5.36
Median: 3.25
Q1: 1.69
Min: -5.59

AstraZeneca (AZN) vs. Genmab (GMAB): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AstraZeneca (AZN) and Genmab (GMAB)
Metric	AZN	GMAB
P/E Ratio (TTM)	26.37	45.84
P/S Ratio (TTM)	4.63	7.68
P/B Ratio (MRQ)	5.59	5.36
Free Cash Flow Yield (TTM)	1.95%	2.59%